Acadian Asset Management’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,233
Closed -$27K 2198
2026
Q1
$27K Sell
3,233
-372,166
-99% -$3.91M ﹤0.01% 1922
2025
Q4
$5.4M Sell
375,399
-23,733
-6% -$296K 0.01% 633
2025
Q3
$3.85M Buy
399,132
+158,868
+66% +$1.41M 0.01% 714
2025
Q2
$1.97M Buy
240,264
+82,998
+53% +$695K ﹤0.01% 834
2025
Q1
$1.12M Buy
+157,266
New +$1.17M ﹤0.01% 910
2024
Q4
Sell
-133,817
Closed -$1.4M 2070
2024
Q3
$1.4M Buy
133,817
+91,525
+216% +$1.12M ﹤0.01% 845
2024
Q2
$494K Buy
+42,292
New +$658K ﹤0.01% 1200
2023
Q1
Sell
-21,873
Closed -$494K 1929
2022
Q4
$494K Buy
+21,873
New +$494K ﹤0.01% 1036
2022
Q3
Sell
-17,804
Closed -$440K 1815
2022
Q2
$440K Buy
+17,804
New +$445K ﹤0.01% 1013
2019
Q3
Sell
-9,778
Closed -$503K 1981
2019
Q2
$503K Sell
9,778
-98,845
-91% -$4.93M ﹤0.01% 1019
2019
Q1
$6.23M Buy
108,623
+88,300
+434% +$4.37M 0.03% 392
2018
Q4
$853K Sell
20,323
-26,084
-56% -$1.53M ﹤0.01% 779
2018
Q3
$3.5M Sell
46,407
-24,459
-35% -$1.76M 0.01% 443
2018
Q2
$5.08M Buy
+70,866
New +$3.38M 0.02% 383
2017
Q2
Sell
-14,107
Closed -$272K 1559
2017
Q1
$272K Buy
+14,107
New +$272K ﹤0.01% 996

Other funds holding RGNX

Acadian Asset Management's RGNX Position: Q2 2026 in Review

Acadian Asset Management sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 3,233 shares — an estimated $27K sold.

Acadian Asset Management first reported a position in RGNX in Q1 2017 and held it in 15 quarters. The position peaked at $6.23M in Q1 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Acadian Asset Management reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 3,233 Regenxbio shares in Q2 2026, an estimated $27K.
  • Acadian Asset Management first reported a position in Regenxbio in Q1 2017 and held it in 15 quarters.
  • Acadian Asset Management's Regenxbio position peaked at $6.23M in Q1 2019.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.